# Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)

> **NCT00802737** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 29 (actual)

## Conditions studied

- Leukaemia, Lymphocytic, Chronic

## Interventions

- **DRUG:** Ofatumumab

## Key facts

- **NCT ID:** NCT00802737
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2011-09
- **Final completion:** 2013-05
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2014-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00802737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00802737, "Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00802737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*